Navigation Links
Tunnell Consulting Joins Top Industry Experts at ISPE Conference

Tunnell Consulting announced today that four of the firm’s thought leaders will be taking part in sessions at the ISPE Annual Meeting and Expo, to be held October 29 through November 1 in San Diego at the Marriott Marquis San Diego Marina. The event’s theme is “Driving innovation to advance patient therapies.”

The ISPE Annual Meeting and Expo will feature several interactive education sessions, focused on significant trends in the pharmaceutical engineering field. This year’s event highlights current industry initiatives designed to transform new medicines and emerging technologies from vision to reality.

Tunnell’s Dr. Philippe Cini will lead a session on Monday, October 30 as part of the event’s Product Development and Production Systems track. The discussion, “Process capabilities as they apply to the pharmaceutical and biotech industry,” is an insightful follow-on to the ISPE Process Capability Workgroup’s earlier article on how process capabilities drive process improvement and compliance. “During this session, attendees can learn more about the work done by the ISPE Process Capability Workgroup, and how pharmaceutical and biotech companies put those programs into action in their own companies,” said Dr. Cini.

Also on Monday, Tunnell’s Greg Anthos will share his insights as he leads the “Quality systems integration for acquisitions/mergers and suppliers” panel, as part of the Quality Systems and Regulatory track. “After a merger, firms need to look at whether their quality systems are in need of an update,” said Anthos. “In any case, quality systems often evolve or have many small revisions over time, and eventually become cumbersome. As part of this session, we will look at how one company redesigned their quality systems in roughly one month, and implemented the new design within six months.” The session will be especially useful for leaders responsible for quality systems, and will include an interactive audience discussion.

As part of the event’s Information Systems track, Tunnell’s Kip Wolf will take a role in the “Data Integrity Concepts – A Broader Approach” session on Tuesday, October 31. During the session, Kip will have copies of his article on data integrity from Life Science Magazine available. During the panel discussion, Kip and other industry thought leaders will explore how key quality principles and processes are the foundation of data integrity assurance for cloud based systems. Techniques for evaluating cloud providers, specifying requirements, and implementing the correct client-side controls will be included as part of a case study, and innovations in information governance will also be discussed. “The impact of cloud-based systems requires a renewed look at data integrity needs and controls,” said Wolf. “During this informative session, we will look at the relationship that exists between recent trends and information governance, and highlight some of the newer opportunities and innovative strategies that can be put into place to reduce risks and improve data integrity in this new environment.”

Also on Tuesday, Julia O’Neill’s session, “Clinically relevant specifications for drug substance and drug product impurities: The why and how,” in the Quality Systems and Regulatory track, looks at the potential drawbacks of current practices, and the benefits of decoupling the voice of the patient from the voice of the process. “The current practice of setting specifications based on variability observed in limited clinical batches, without considering the impact on the patient, may reward poor manufacturing process,” said O’Neill. “Drawbacks of this approach include the fact that it may reject a batch that could have met patients’ needs, and it may also lead to drug shortages and higher costs.”

The Tunnell thought leaders participating in the event are at the forefront of the industry, guiding the most important decisions pharmaceutical and life sciences companies must make. The speakers not only understand the industry as it is now, but where it is going in the years to come.

About Tunnell Consulting
Founded in 1962 and serving many of the world’s leading life sciences firms and government agencies, Tunnell Consulting, Inc. integrates strategic, technical, process, and organizational skills to design and implement sustainable solutions that exactly meet client needs. With deep industry knowledge, extensive scientific credentials, and superior measurable results, we consistently boost the operating performance of each unique client we serve. To learn more, visit us online at

Read the full story at

Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved

Related biology technology :

1. Tunnell Consulting’s Kip Wolf Delivers Insights into the Future of Pharmaceuticals Industry
2. Tunnell Consulting Strengthens Regulatory Affairs Team with Addition of Industry Veteran Kati Abraham
3. Julia O’Neill of Tunnell Consulting Shares Process Validation Insights at Pharma Conference
4. Frédéric Lefebvre Joins Tunnell Consulting as Director Focused on Business Development in Europe
5. Dr. Walter Matzmorr Joins Tunnell Consulting
6. Gerard (Jerry) Guillorn Joins Tunnell Consulting As Group Vice President, Business Development
7. Julia O’Neill Joins Tunnell Consulting’s Operational and Process Improvement Practice
8. Tunnell Consulting Partners with Dr. Ajaz Hussain on Solutions for Life Sciences Product Development, Quality Assurance and Regulatory Compliance
9. Anthony A. Charity Joins Tunnell Consulting
10. Tunnell Consulting Names John S. Ross as Principal, Life Sciences
11. Trinity Sterile Selects The Copley Consulting Group to Implement Infor’s CloudSuite Industrial (Syteline)™ Solution
Post Your Comments:
(Date:10/11/2017)... ... 2017 , ... Disappearing forests and increased emissions are the main causes of ... year. Especially those living in larger cities are affected by air pollution related diseases. ... most pollution-affected countries globally - decided to take action. , “I knew I had ...
(Date:10/10/2017)... (PRWEB) , ... October 10, ... ... development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed ... targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with ...
(Date:10/10/2017)... Calif. , Oct. 10, 2017 SomaGenics ... from the NIH to develop RealSeq®-SC (Single Cell), expected ... for profiling small RNAs (including microRNAs) from single cells ... Program highlights the need to accelerate development of approaches ... "New techniques for measuring levels ...
(Date:10/9/2017)... (PRWEB) , ... October 09, 2017 , ... The award-winning ... to broadcast first quarter 2018. American Farmer airs Tuesdays at 8:30aET on RFD-TV. ... is faced with the challenge of how to continue to feed a growing nation. ...
Breaking Biology Technology:
(Date:4/6/2017)... Forecasts by Product Type (EAC), Biometrics, Card-Based ... & Logistics, Government & Public Sector, Utilities / Energy ... Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality & ... for a definitive report on the $27.9bn Access Control ... ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/28/2017)... , March 28, 2017 ... Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video ... and Region - Global Forecast to 2022", published by ... in 2016 and is projected to reach USD 75.64 ... 2017 and 2022. The base year considered for the ...
Breaking Biology News(10 mins):